DRMA
Dermata Therapeutics, Inc.Company Information
- Company Name
- Dermata Therapeutics, Inc.
- CIK
- CIK0001853816
- Category
- <br>Emerging growth company
- Ticker: Exchange
- DRMA: Nasdaq, DRMAW: Nasdaq
- Fiscal Year End
- December 31
- Owner Organization
- 03 Life Sciences
- SIC
- 2834
- SIC Description
- Pharmaceutical Preparations
- Ticker
- DRMA
SEC filing data through
Insider Sentiment
- Last purchase
- 2026-02-17
- Last sale
- 2026-06-16
- Shares purchased (TTM)
- 1,000
- Shares sold (TTM)
- 11
Institutional Sentiment
- As of
- 2026-06-30
- Institutional shares owned
- 122,513
- Shares outstanding
- 4,022,143
- Ownership
- 3.05%
Earnings Market Reaction
- Filing date
- 2026-08-11
- Price on filing date
- —
- 1-month reaction
- 12.04%
- 3-month reaction
- …
Balance Sheet
Values in millions ($)| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash And Cash Equivalents At Carrying Value | 4 | 7 | 8 | 5 | 6 | 10 | 3 | 6 | 5 | 5 | 7 | 7 | ||||||
| Prepaid Expense And Other Assets Current | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 1 | ||||||
| Inventory Net | 0 | 0 | - | - | - | - | - | - | - | - | - | - | ||||||
| Property Plant And Equipment Net | 0 | - | - | - | - | - | - | - | - | - | - | - | ||||||
| Other Assets | 0 | - | - | - | - | - | - | - | - | - | - | - | ||||||
| Assets | 5 | 7 | 8 | 5 | 7 | 10 | 4 | 7 | 5 | 5 | 8 | 7 | ||||||
Liabilities And Stockholders Equity | ||||||||||||||||||
| Accounts Payable Current | 1 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | ||||||
| Accrued Liabilities And Other Liabilities | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | - | ||||||
| Assets Current | 5 | - | - | - | - | - | - | - | - | - | - | - | ||||||
Commitments And Contingencies Disclosure | ||||||||||||||||||
| Liabilities | 2 | 1 | 2 | 1 | 1 | 3 | 2 | 2 | 2 | 1 | 2 | 1 | ||||||
Stockholders Equity | ||||||||||||||||||
| Common Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Stockholders Equity | 3 | 6 | 6 | 4 | 6 | 7 | 2 | 5 | 3 | 4 | 6 | 6 | ||||||
| Additional Paid In Capital | 82 | 81 | 79 | 75 | 75 | 75 | 67 | 67 | 63 | 60 | 60 | 58 | ||||||
| Retained Earnings Accumulated Deficit | -78 | -75 | -73 | -71 | -70 | -68 | -66 | -63 | -59 | -57 | -53 | -51 | ||||||
| Liabilities And Stockholders Equity | 5 | 7 | 8 | 5 | 7 | 10 | 4 | 7 | 5 | 5 | 8 | 7 | ||||||
| Other Accrued Liabilities Current | 0 | 0 | 0 | 0 | - | - | 0 | - | - | - | - | 0 | ||||||
| Common Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Preferred Stock Par Or Stated Value Per Share | - | 0.00 | - | 0.00 | - | - | - | - | - | - | - | - | ||||||
| Common Stock Shares Authorized | 250 | 250 | 250 | 250 | 250 | 250 | 250 | 250 | 250 | 250 | 250 | 250 | ||||||
| Preferred Stock Shares Authorized | - | 10 | - | 10 | - | - | - | - | - | - | - | - | ||||||
| Common Stock Shares Issued | 4 | 4 | 3 | 1 | 1 | 1 | 0 | 0 | 0 | 1 | 0 | 0 | ||||||
| Preferred Stock Shares Issued | - | 0 | - | 0 | - | - | - | - | - | - | - | - | ||||||
| Shares Outstanding | 4 | 4 | 3 | 1 | 1 | 1 | 0 | 0 | 0 | 1 | 0 | 0 | ||||||
| Preferred Stock Shares Outstanding | - | 0 | - | 0 | - | - | - | - | - | - | - | - | ||||||
Select a line item above to chart it.
Recent filings
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialDermata Therapeutics, Inc. (DRMA) — SEC Financial Statements & Analysis
Dermata Therapeutics, Inc. (DRMA) is a pharmaceutical preparations company, incorporated in DE. Dermata Therapeutics, Inc. trades on Nasdaq as: DRMA, DRMAW. Dermata Therapeutics, Inc. (DRMA)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-11. Based on that filing, Dermata Therapeutics, Inc. carries a market cap of $5.19M, a P/E ratio of -0.62x, a P/B ratio of 1.49x, an enterprise value of $775.80K, and an EV/EBITDA multiple of -0.09x. On profitability, it posts a Return on Equity (ROE) of -183.89% and a Return on Assets (ROA) of -157.28%. Per share, it reports EPS of $-2.08, diluted EPS of $-2.08, free cash flow per share of $-2.03, and a dividend per share of $0.00. Over the trailing year, it posted net income growth of -18.98% year-over-year and EPS growth of -79.32% year-over-year. On the balance sheet, it maintains an interest coverage ratio of -109.08x, free cash flow of $-8.14M (TTM), and net debt of $-4.41M. Figures sourced from SEC EDGAR.
- Market Cap
- $5.19M
- P/E TTM
- -0.62x
- EPS TTM
- $-2.08
- P/B TTM
- 1.49x
- ROE TTM
- -183.89%
- ROA TTM
- -157.28%
- Free Cash Flow TTM
- $-8.14M
Data as of 2026-06-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is Dermata Therapeutics, Inc. in?
Dermata Therapeutics, Inc. (DRMA) operates in the Pharmaceutical Preparations industry.
What exchange does DRMA trade on?
Dermata Therapeutics, Inc. (DRMA) trades on the Nasdaq.
Where is Dermata Therapeutics, Inc. incorporated?
Dermata Therapeutics, Inc. is incorporated in DE.
When was Dermata Therapeutics, Inc. (DRMA)'s most recent SEC filing?
Dermata Therapeutics, Inc. (DRMA)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-11.
What is DRMA's market cap?
Dermata Therapeutics, Inc. (DRMA) has a market capitalization of $5.19M as of 2026-06-30.
What is DRMA's EPS (earnings per share)?
Dermata Therapeutics, Inc. (DRMA)'s trailing twelve month EPS is $-2.08 as of 2026-06-30.
What is DRMA's ROE (return on equity)?
Dermata Therapeutics, Inc. (DRMA)'s trailing twelve month Return on Equity (ROE) is -183.89% as of 2026-06-30.
What is DRMA's ROA (return on assets)?
Dermata Therapeutics, Inc. (DRMA)'s trailing twelve month Return on Assets (ROA) is -157.28% as of 2026-06-30.
What is DRMA's EV/EBITDA?
Dermata Therapeutics, Inc. (DRMA)'s trailing twelve month EV/EBITDA is -0.09x as of 2026-06-30.